Type 2 DiabetesMiniExNCT04129268
Determining the Minimal Amount of Exercise to Improve Glycaemic Control
A study testing Cycle ergometry exercise at 60% VO2max in people with Type 2 Diabetes, run by Lancaster University at 1 site in United Kingdom.
Trial summary
In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, typeII diabetes will affect one in ten adults worldwide. Type II diabetes reduces quality of life and total lifespan, and two of the best countermeasures to type II diabetes are not drugs, but diet and exercise. Read more about this study
- Who is it for?
- Ages 18 to 80 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- Cycle ergometry exercise at 60% VO2max
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 Oct 2019to 29 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Aged 18 years and upwards
- Capacity to consent to participation
- Diagnosis of type II diabetes
- BMI >25
- Aged 18 - 40
- Capacity to consent to participation
Show all 10Show fewer
- BMI >25
- Aged >60
- Capacity to consent to participation
- BMI >25
Who cannot join
- Patient is aged under 18 years
- Patient lacks capacity to consent to participation
- Anything that investigators feel affects the study measurements or safety
- Cohort 2: 9 young control subjects under the following criteria:
- Subject is aged under 18 years
- Subject lacks capacity to consent to participation
Show all 13Show fewer
- Subject on medication that affects glycaemic control
- Anything that investigators feel affects the study measurements or safety
- Cohort 3: 9 older control subjects under the following criteria:
- Subject is aged under 18 years
- Subject lacks capacity to consent to participation
- Subject on medication that affects glycaemic control
- Anything that investigators feel affects the study measurements or safety
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Determining the Minimum Amount of Exercise to Improve Glycaemic Control in Young and Old Overweight Males, and in Patients With Type II Diabetes
In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, typeII diabetes will affect one in ten adults worldwide. Type II diabetes reduces quality of life and total lifespan, and two of the best countermeasures to type II diabetes are not drugs, but diet and exercise. Several studies have investigated the effects of exercise modality (aerobic, resistance, or concurrent) on glycaemic control and the mechanisms of these benefits. However, the minimal 'dose' of exercise required to increase insulin sensitivity and improve glycaemic control has never been established. Secondly, there is a progressive loss of muscle structure and function with age, which is known as sarcopenia. This study will also investigate whether the minimal amount of exercise is influenced by biological age and muscle mass by comparing physiological and biochemical responses in BMI-matched young and old volunteers. This study will therefore provide pilot data on the effect of age on exercise-mediated glycaemic control.
Read the detailed description
Background Information and rationale Overarching aim: The purpose of this study is to identify the minimum number of calories that must be expended to improve the control of blood glucose in young and older overweight males, and in those with type II diabetes.
Why is this important? In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, type II diabetes will affect one in ten adults worldwide. If the minimal volume of exercise to improve glycaemic control can be established, this could increase exercise compliance and population health.
Current knowledge and preliminary data Acute exercise improves glycaemic control by promoting the translocation of the glucose transporter GLUT-4 in an insulin-independent pathway. This mechanism is intact even in patients with type II diabetes. An acute bout of exercise for ~70 mins at 65% VO2max (energy expenditure of 350kcal) improves insulin sensitivity by ~15% 1h after exercise, and ~30% the day following exercise in obese adults. This improved insulin sensitivity is also associated with a 17% reduction in circulating free fatty acids, which chronically might benefit both type II diabetes and cardiovascular disease - a major secondary complication of type II diabetes. Several studies have investigated the effects of exercise modality (aerobic, resistance, or concurrent) on glycaemic control and the mechanisms of these benefits (8). However, the minimal 'dose' of exercise required to increase insulin sensitivity and improve glycaemic control has never been established. Secondly, there is a progressive loss of muscle structure and function with age, which is known as sarcopenia. This study will also investigate whether the minimal amount of exercise is influenced by biological age and muscle mass by comparing physiological and biochemical responses in BMI-matched young and old volunteers. Establishing the dose-response relationship for exercise and glycaemic control. It is important to establish the optimal dose-response relationship for exercise and glycaemic control in order to maximise the health benefits and minimize side-effects of the exercise intervention. Whilst the risks of exercise are low unless undertaking athlete-level training for several years, establishing the minimum exercise required for glycaemic control would improve exercise adherence. Indeed, lower volumes of exercise are easier to maintain than larger volumes, and this has led to the adoption of short-duration exercise strategies for glycaemic control, such as high intensity interval training.
Previous work has shown that an acute bout of cycling expending 350kcal can increase insulin sensitivity by ~30% the day following exercise in obese adults. On this basis, the proposed study will test three levels of kcal expenditure: 1) a 350kcal intervention, which is predicted to increase insulin sensitivity in line with; 2) a 700kcal intervention, to deliver a profound (doubling) stimulus to increase insulin sensitivity; and 3) 175kcal intervention, to examine the efficacy of a halved stimulus on insulin sensitivity. These three intervention points are necessary in order to accurately model the dose response relationship between amount of exercise and insulin sensitivity, which is currently unknown. There will also be a no exercise trial where the same data are collected and used to calculate baseline glycaemic control/insulin sensitivity from which any increase prompted by exercise can be determined. If the minimal volume of exercise to improve glycaemic control can be established, this could increase exercise compliance and population health. This minimal amount of exercise may increase in older subjects where muscle mass and quality is reduced. This study will therefore provide pilot data on the effect of age on exercise-mediated glycaemic control.
Objectives of the study Recruitment and testing will take place throughout the first 15 months of the study, allowing 3 months at the end of the study for data analysis. The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise trials the day before an oral glucose tolerance test (OGTT). An acute bout of 350kcal exercise can improve insulin sensitivity by ~30% the following day; the trials in the proposed study intend to result in: (i) baseline glycaemic control; (ii) small improvements in glycaemic control; (iii) ~30% improvement in glycaemic control; and (iv) large >30% improvement in glycaemic control. The OGTT, continuous glucose monitoring (CGM), measurement of insulin, and FFA will be used to calculate dose response curves in each of these individual variables, where the minimum amount of exercise to improve glycaemic control can be ascertained.
- Conditions
- Type 2 Diabetes
- Being tested
- Cycle ergometry exercise at 60% VO2max
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cycle ergometry exercise at 60% VO2maxOther
Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).
| Study group | Role | What they receive |
|---|---|---|
| No exercise control | Other | The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis. Receives: Other: Cycle ergometry exercise at 60% VO2max |
| 175kcal Cycle ergometry exercise at 60% VO2max | Experimental | The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis. Receives: Other: Cycle ergometry exercise at 60% VO2max |
| 350kcal Cycle ergometry exercise at 60% VO2max | Experimental | The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis. Receives: Other: Cycle ergometry exercise at 60% VO2max |
| 700kcal Cycle ergometry exercise at 60% VO2max | Experimental | The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT).
350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis. Receives: Other: Cycle ergometry exercise at 60% VO2max |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities
The investigators will quantify the lowering of blood glucose values during the OGTT 24h following 175kcal, 350kcal and 700kcal exercise when compared to a no exercise control.
Measured: over the 8 weeks of participant involvement in study
Secondary outcomes (1)
Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities
The investigators will quantify the lowering of serum insulin values during the OGTT 24h following 175kcal, 350kcal and 700kcal exercise when compared to a no exercise control.
Measured: over the 8 weeks of participant involvement in study
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Oct 2019
- Study start1 Oct 2019
- Primary completion26 Sep 2022
- Study completion29 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lancaster University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Chris Gaffney, Lancaster University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04129268
- Sponsor's protocol ID
- 248319
- Other IDs
- 19/NW/0066
- Acronym
- MiniEx
- Status last verified
- May 2023
- First submitted
- 9 Oct 2019
- Last updated
- 22 May 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Determining the Minimum Amount of Exercise to Improve Glycaemic Control in Young and Old Overweight Males, and in Patients With Type II Diabetes
- ClinicalTrials.gov ID
- NCT04129268
- Acronym / sponsor ID
- MiniEx / 248319
- Conditions
- Type 2 Diabetes
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Lancaster UniversityUniversity, hospital or other
- Study start
- 1 Oct 2019 (actual)
- Primary completion
- 26 Sep 2022 (actual)
- Study completion
- 29 Sep 2022 (actual)
- First posted
- 16 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, typeII diabetes will affect one in ten adults worldwide. Type II diabetes reduces quality of life and total lifespan, and two of the best countermeasures to type II diabetes are not drugs, but diet and exercise. Several studies have investigated the effects of exercise modality (aerobic, resistance, or concurrent) on glycaemic control and the mechanisms of these benefits. However, the minimal 'dose' of exercise required to increase insulin sensitivity and improve glycaemic control has never been established. Secondly, there is a progressive loss of muscle structure and function with age, which is known as sarcopenia. This study will also investigate whether the minimal amount of exercise is influenced by biological age and muscle mass by comparing physiological and biochemical responses in BMI-matched young and old volunteers. This study will therefore provide pilot data on the effect of age on exercise-mediated glycaemic control.
Detailed description
Background Information and rationale Overarching aim: The purpose of this study is to identify the minimum number of calories that must be expended to improve the control of blood glucose in young and older overweight males, and in those with type II diabetes.
Why is this important? In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, type II diabetes will affect one in ten adults worldwide. If the minimal volume of exercise to improve glycaemic control can be established, this could increase exercise compliance and population health.
Current knowledge and preliminary data Acute exercise improves glycaemic control by promoting the translocation of the glucose transporter GLUT-4 in an insulin-independent pathway. This mechanism is intact even in patients with type II diabetes. An acute bout of exercise for ~70 mins at 65% VO2max (energy expenditure of 350kcal) improves insulin sensitivity by ~15% 1h after exercise, and ~30% the day following exercise in obese adults. This improved insulin sensitivity is also associated with a 17% reduction in circulating free fatty acids, which chronically might benefit both type II diabetes and cardiovascular disease - a major secondary complication of type II diabetes. Several studies have investigated the effects of exercise modality (aerobic, resistance, or concurrent) on glycaemic control and the mechanisms of these benefits (8). However, the minimal 'dose' of exercise required to increase insulin sensitivity and improve glycaemic control has never been established. Secondly, there is a progressive loss of muscle structure and function with age, which is known as sarcopenia. This study will also investigate whether the minimal amount of exercise is influenced by biological age and muscle mass by comparing physiological and biochemical responses in BMI-matched young and old volunteers. Establishing the dose-response relationship for exercise and glycaemic control. It is important to establish the optimal dose-response relationship for exercise and glycaemic control in order to maximise the health benefits and minimize side-effects of the exercise intervention. Whilst the risks of exercise are low unless undertaking athlete-level training for several years, establishing the minimum exercise required for glycaemic control would improve exercise adherence. Indeed, lower volumes of exercise are easier to maintain than larger volumes, and this has led to the adoption of short-duration exercise strategies for glycaemic control, such as high intensity interval training.
Previous work has shown that an acute bout of cycling expending 350kcal can increase insulin sensitivity by ~30% the day following exercise in obese adults. On this basis, the proposed study will test three levels of kcal expenditure: 1) a 350kcal intervention, which is predicted to increase insulin sensitivity in line with; 2) a 700kcal intervention, to deliver a profound (doubling) stimulus to increase insulin sensitivity; and 3) 175kcal intervention, to examine the efficacy of a halved stimulus on insulin sensitivity. These three intervention points are necessary in order to accurately model the dose response relationship between amount of exercise and insulin sensitivity, which is currently unknown. There will also be a no exercise trial where the same data are collected and used to calculate baseline glycaemic control/insulin sensitivity from which any increase prompted by exercise can be determined. If the minimal volume of exercise to improve glycaemic control can be established, this could increase exercise compliance and population health. This minimal amount of exercise may increase in older subjects where muscle mass and quality is reduced. This study will therefore provide pilot data on the effect of age on exercise-mediated glycaemic control.
Objectives of the study Recruitment and testing will take place throughout the first 15 months of the study, allowing 3 months at the end of the study for data analysis. The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise trials the day before an oral glucose tolerance test (OGTT). An acute bout of 350kcal exercise can improve insulin sensitivity by ~30% the following day; the trials in the proposed study intend to result in: (i) baseline glycaemic control; (ii) small improvements in glycaemic control; (iii) ~30% improvement in glycaemic control; and (iv) large >30% improvement in glycaemic control. The OGTT, continuous glucose monitoring (CGM), measurement of insulin, and FFA will be used to calculate dose response curves in each of these individual variables, where the minimum amount of exercise to improve glycaemic control can be ascertained.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| No exercise control | Other | Other: Cycle ergometry exercise at 60% VO2maxThe investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis. |
| 175kcal Cycle ergometry exercise at 60% VO2max | Experimental | Other: Cycle ergometry exercise at 60% VO2maxThe investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis. |
| 350kcal Cycle ergometry exercise at 60% VO2max | Experimental | Other: Cycle ergometry exercise at 60% VO2maxThe investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis. |
| 700kcal Cycle ergometry exercise at 60% VO2max | Experimental | Other: Cycle ergometry exercise at 60% VO2maxThe investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Aged 18 years and upwards
- Capacity to consent to participation
- Diagnosis of type II diabetes
- BMI >25
- Aged 18 - 40
Key exclusion criteria (13 listed)
- Patient is aged under 18 years
- Patient lacks capacity to consent to participation
- Anything that investigators feel affects the study measurements or safety
- Subject is aged under 18 years
- Subject lacks capacity to consent to participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cycle ergometry exercise at 60% VO2maxParticipants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised). | Other | 175kcal Cycle ergometry exercise at 60% VO2max, 350kcal Cycle ergometry exercise at 60% VO2max, 700kcal Cycle ergometry exercise at 60% VO2max, No exercise control |
Primary outcome
Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities
Time frame: over the 8 weeks of participant involvement in study
The investigators will quantify the lowering of blood glucose values during the OGTT 24h following 175kcal, 350kcal and 700kcal exercise when compared to a no exercise control.
1 secondary outcome
Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities
Time frame: over the 8 weeks of participant involvement in study
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 May 2023.
- Individual participant dataSharing planned: No
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cycle ergometry exercise at 60% VO2max in people with Type 2 Diabetes, run by Lancaster University at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities (time frame: over the 8 weeks of participant involvement in study). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2023.